|
[1] CHENG AL,KANG YK,CHEN Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:A phase III randomised,doubleblind,placebo-controlled trial[J]. Lancet Oncol,2009,10(1):25-34.
|
|
[2] CURTIT E,THIERY-VUILLEMIN A,NGUYEN T,et al. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma:A case report[J]. J Clin Oncol,2011,29(12):e330-e332.
|
|
[3] IRTAN S,CHOPIN-LALY X,RONOT M,et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection[J]. Liver Int,2011,31(5):740-743.
|
|
[4] BARBIER L,MUSCARI F,LE GUELLEC S,et al. Liver resection after downstaging hepatocellular carcinoma with sorafenib[J]. Int J Hepatol,2011,2011:791013.
|
|
[5] WILLIET N,DUBREUIL O,BOUSSAHA T,et al. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma[J]. World J Gastroenterol,2011,17(17):2255-2258.
|
|
[6] DEGUCHI S,TSUKAMOTO T,KANAZAWA A,et al. A case of multiple HCC with Vp2 and Vp3 invasion controlled by multidisciplinary treatment including surgery[J]. Cancer Chemother,2015,42(12):1845-1847.
|
|
[7] IKEDA M,OKUSAKA T,MITSUNAGA S,et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res,2016,22(6):1385-1394.
|
|
[8] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
|
[9] ZHU AX,FINN RS,EDELINE J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952.
|
|
[10] QIN S,BAI Y,LIM HY,et al. Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol,2013,31(28):3501-3508.
|
|
[11] Chinese Society of Radiation Oncology,Chinese Medical Association; Liver Cancer Study Group and Expert Committee on Digestive System Neoplasms,Precise Radiotherapy Branch,Chinese Society of Biomedical Engineering; Liver Cancer Study Group,Radiation Oncology Branch,Chinese Research Hospital Association. Consensus on radiation therapy for primary liver cancer in 2016[J]. Chin J Radiat Oncol,2016,25(11):1141-1150.(in Chinese)中华医学会放射肿瘤学分会，中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会，中国研究型医院学会放射肿瘤学分会肝癌学组．2016年原发性肝癌放疗共识[J]．中华放射肿瘤学杂志，2016,25(11):1141-1150.
|
|
[12] ZENG ZC,TANG ZY,FAN J,et al. A comparison of treatment combinations with and without radiotherapy for the hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]. Oncol Progr,2006,4(4):284-307.(in Chinese)曾昭冲，汤钊猷，樊嘉，等．肝细胞肝癌伴门静脉/下腔静脉癌栓接受与不接受放射治疗的比较[J]．癌症进展，2006,4(4):284-307.
|
|
[13] KUDO M. Immuno-oncology in hepatocellular carcinoma:2017 update[J]. Oncology,2017,93(Suppl 1):147-159.
|
|
[14] IKEDA M,SUNG MW,KUDO M,et al. A phase Ib trial of lenvatinib(LEN)plus pembrolizumab(PEMBRO)in unresectable hepatocellular carcinoma(u HCC):Updated results[C].2019 ESMO poster 747P,2019.
|
|
[15] KEENAN B,GRIFFITH MJ,BAUER K,et al. Phase II multicenter pilot study of safety,efficacy,and immune cell profiling in advanced hepatocellular carcinoma(HCC)on combination of sorafenib(SOR)plus nivolumab(NIVO)[J]. J Clin Oncol,2019,37(4 Suppl):TPS464.
|
|
[16] SPENCER KR,RAMSINGH G,MOHAMED N,et al. Phase Ib trial of cabozantinib(C)in combination with atezolizumab(A)in patients(pts)with advanced hepatocellular carcinoma(HCC),gastric or gastroesophageal junction cancer(GC/GEJC),or colorectal cancer(CRC)[J]. J Clin Oncol,2019,37(4 Suppl):TPS478.
|
|
[17] LIU GY,LIU Y,ZHANG YW. TACE combined with sorafenib in the treatment of advanced HCC preliminary evaluation of the efficacy and safety[J/CD]. Electr J Liver Tumor,2018,5(2):19-23.(in Chinese)刘广宇，刘影，张跃伟．TACE联合索拉非尼治疗中晚期肝细胞肝癌疗效及安全性初步评价[J/CD]．肝癌电子杂志，2018,5(2):19-23.
|
|
[18] ZHANG YF,WEI W,WANG JH,et al. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus[J]. Onco Targets Ther,2016,9:4239-4246.
|
|
[19] CHAO Y,CHUNG YH,HAN G,et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma:final results of the START trial[J]. Int J Cancer,2015,136:1458-1467.
|
|
[20] MENG MB,CUI YL,LU Y,et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma:A systematic review and metaanalysis[J]. Radiother Oncol,2009,92(2):184-194.
|
|
[21] SEONG J,LEE IJ,SHIM SJ,et al. A multicenter retrospective cohort study of practice and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea[J]. Liver Int,2009,29(2):147-152.
|
|
[22] HSU HC,CHEN TY,CHIU KW,et al. Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma[J]. Br J Radiol,2007,80(949):38-42.
|
|
[23] KUDO M. Locoregional therapy for hepatocellular carcinoma[J]. Liver Cancer,2015,4(3):163-164.
|
|
[24] KUDO M. Surveillance,diagnosis,treatment,and outcome of liver cancer in Japan[J]. Liver Cancer,2015,4(1):39-50.
|
|
[25] TSURUSAKI M,MURAKAMI T. Surgical and locoregional therapy of HCC:TACE[J]. Liver Cancer,2015,4(3):165-175.
|
|
[26] ARIZUMI T,UESHIMA K,MINAMI T,et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization(TACE)refractory and intermediate-stage hepatocellular carcinoma[J]. Liver Cancer,2015,4(4):253-262.
|
|
[27] TENG W,LIU KW,LIN CC,et al. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation[J]. Liver Cancer,2015,4(1):26-38.
|
|
[28] KANG TW,RHIM H. Recent advances in tumor ablation for hepatocellular carcinoma[J]. Liver Cancer,2015,4(3):176-187.
|
|
[29] LENCIONI R,de BAERE T,MARTIN RC,et al. Imageguided ablation of malignant liver tumors:Recommendations for clinical validation of novel thermal and non-thermal technologies-a Western perspective[J]. Liver Cancer,2015,4(4):208-214.
|
|
[30] KUDO M. Immune checkpoint inhibition in hepatocellular carcinoma:Basics and ongoing clinical trials[J]. Oncology,2017,92(Suppl 1):50-62.
|
|
[31] MIZUKOSHI E,YAMASHITA T,ARAI K,et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology,2013,57(4):1448-1457.
|
|
[32] LEE IJ,KIM JW,HAN KH,et al. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma[J]. Yonsei Med J,2014,55(6):1489-1497.
|
|
[33] CHEN SW,LIN LC,KUO YC,et al. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys,2014,88(5):1041-1047.
|
|
[34] KIM JH,PARK JW,KIM TH,et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2007,69(3):813-819.
|
|
[35] QIN SK,DONG JH,LU SC,et al. Clinical registry of primary liver cancer in China:A preliminary report[C]. The 20th National Congress of Clinical Oncology&The 2017 Annual Meeting of Chinese Society of Clinical Oncology. Xiamen,2017.(in Chinese)秦叔逵，董家鸿，卢实春，等．《中国原发性肝癌临床登记调查初步报告》[C]．第二十届全国临床肿瘤学大会暨2017年CSCO学术年会．厦门，2017.
|
|
[36] KUDO M,MATILLA A,SANTORO A,et al. Checkmate-040:Nivolumab(NIVO)in patients with advanced hepatocellular carcinoma and Child-Pugh B(CPB)status[J]. J Clin Oncol,2019,37(Suppl 4):327.
|
|
[37] Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virusrelated hepatocellular carcinoma[J]. J Clin Hepatol,2014,30(5):390-395.(in Chinese)肝细胞癌抗病毒治疗专家组．HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J]．临床肝胆病杂志，2014,30(5):390-395.
|
DownLoad: